Stromal re-engineering to treat pancreas cancer

Ingunn M. Stromnes, Kathleen E. DelGiorno, Philip D. Greenberg, Sunil R. Hingorani

Research output: Contribution to journalArticlepeer-review

103 Scopus citations


Pancreatic ductal adenocarcinoma co-opts multiple cellular and extracellular mechanisms to create a complex cancer organ with an unusual proclivity for metastasis and resistance to therapy. Cellautonomous events are essential for the initiation and maintenance of pancreatic ductal adenocarcinoma, but recent studies have implicated critical non-cell autonomous processes within the robust desmoplastic stroma that promote disease pathogenesis and resistance. Thus, nonmalignant cells and associated factors are culprits in tumor growth, immunosuppression, and invasion. However, even this increasing awareness of non-cell autonomous contributions to disease progression is tempered by the conflicting roles stromal elements can play. A greater understanding of stromal complexity and complicity has been aided in part by studies in highly faithful genetically engineered mouse models of pancreatic ductal adenocarcinoma. Insights gleaned from such studies are spurring the development of therapies designed to re-engineer the pancreas cancer stroma and render it permissive to agents targeting cell-autonomous events or to reinstate immunosurveillance. Integrating conventional and immunological treatments in the context of stromal targeting may provide the key to a durable clinical impact on this formidable disease.

Original languageEnglish (US)
Article numberbgu115
Issue number7
StatePublished - Jul 2014


  • Immunotherapy
  • Interstitial fluid pressure
  • Pancreatic cancer
  • Pancreatic ductal adenocarcinoma
  • Stromal resistance


Dive into the research topics of 'Stromal re-engineering to treat pancreas cancer'. Together they form a unique fingerprint.

Cite this